Company patents
INNATE PHARMA
INNATE PHARMA's patent strategy is heavily concentrated in Peptides & Proteins, representing 92.9% of its portfolio, yet patenting in this core area has seen a significant decline of 33.3% in 2025 and a further 85.7% so far in 2026, suggesting a potential shift in focus or a maturation of its core R&D pipeline, despite a 40.0% growth in 2024. The complete cessation of patenting in Material & Chemical Analysis so far in 2026, after consistent activity, also indicates a shifting priority away from this area.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
56 US filings (since 2023) · 4 categories · 10 themes
Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.
Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.
Therapeutic interventions that target immune checkpoint pathways to either enhance or suppress immune responses, often used in cancer immunotherapy or autoimmune diseases.
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Methods and compositions for identifying, quantifying, or characterizing specific biological molecules (e.g., nucleic acids, proteins, metabolites, antibodies) or microbial species, often for diagnostic, prognostic, or quality control applications.
Therapeutic approaches involving the use of living cells, often genetically modified or ex vivo activated, to treat diseases, particularly cancer, by modulating immune responses or replacing damaged cells.
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.
Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.
Methods and systems for the efficient and scalable production, purification, and formulation of proteins and peptides, including fermentation, chromatography, and cell-based expression systems.
Patents
Showing 1-10 of 23
Cellular Immunotherapy